Comprehensive review of epidemiological and animal studies on the potential carcinogenic effects of nicotine per se

Critical Reviews in Toxicology

Volumn 46, Issue 8, 2016, Pages 701-734

  Haussmann, Hans Juergen ^a   Fariss, Marc W ^b  

^a Toxicology Consultant   (Germany)

^b Altria Client Services   (United States)

Author keywords

Bioassay; cancer; carcinogenesis; cotinine; epidemiology; nicotine; toxicokinetics; xenograft

Indexed keywords

4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANONE; CARCINOGEN; COTININE; CYCLOPHOSPHAMIDE; ERLOTINIB; ESTRADIOL; NICOTINE; NICOTINE GUM; NICOTINE LOZENGE; NICOTINE N' OXIDE; NICOTINE TARTRATE; NITROSONORNICOTINE;

BIOASSAY; BIOLOGICAL MONITORING; CANCER CELL; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER RISK; CARCINOGENESIS; CLINICAL EVALUATION; DRUG ABSORPTION; DRUG CARCINOGENICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; EMBASE; GENOTOXICITY; HEALTH HAZARD; HUMAN; IMMUNOCOMPETENCE; IN VITRO STUDY; IN VIVO STUDY; INHALATION; INOCULATION; LEIOMYOSARCOMA; LONG TERM EXPOSURE; LUNG CANCER; MEDLINE; NEOPLASM; NICOTINE REPLACEMENT THERAPY; NONHUMAN; OSMOTIC MINIPUMP; PHYSICAL CHEMISTRY; PRACTICE GUIDELINE; REVIEW; RHABDOMYOSARCOMA; SCORING SYSTEM; SYSTEMATIC REVIEW; TOXICOKINETICS; TRANSGENIC ANIMAL; TUMOR XENOGRAFT; ANIMAL; ANIMAL MODEL; POPULATION AND POPULATION RELATED PHENOMENA;

ANIMALS; CARCINOGENS; EPIDEMIOLOGIC MEASUREMENTS; HUMANS; MODELS, ANIMAL; NICOTINE;

EID: 84983050153     PISSN: 10408444     EISSN: 15476898     Source Type: Journal    
DOI: 10.1080/10408444.2016.1182116     Document Type: Review

References (170)

1. H.A.N.Al-Wadei, M.H.Al-Wadei, M.F.Ullah, H.M.Schuller 2012. Gamma-amino butyric acid inhibits the nicotine-imposed stimulatory challenge in xenograft models of non-small cell lung carcinoma. Curr Cancer Drug Targets. 12:97–106.
2. H.A.N.Al-Wadei, H.K.PlummerIII, H.M.Schuller 2009. Nicotine stimulates pancreatic cancer xenografts by systemic increase in stress neurotransmitters and suppression of the inhibitory neurotransmitter γ-aminobutyric acid. Carcinogenesis. 30:506–511.
3. D.J.Alexander, C.J.Collins, D.W.Coombs, I.S.Gilkison, C.J.Hardy, G.Healey, G.Karantabias, N.Johnson, A.Karlsson, J.D.Kilgour,. 2008. Association of Inhalation Toxicologists (AIT) working party recommendation for standard delivered dose calculation and expression in non-clinical aerosol inhalation toxicology studies with pharmaceuticals. Inhal Toxicol. 20:1179–1189.
4. S.D.AlSharari, H.I.Akbarali, R.A.Abdullah, O.Shahab, W.Auttachoat, G.A.Ferreira, K.L.White, A.H.Lichtman, G.A.Cabral, M.I.Damaj 2013. Novel insights on the effect of nicotine in a murine colitis model. J Pharmacol Exp Ther. 344:207–217.
5. I.Arany, S.Grifoni, J.S.Clark, E.Csongradi, C.Maric, L.A.Juncos 2011. Chronic nicotine exposure exacerbates acute renal ischemic injury. Am J Physiol Renal Physiol. 301:F125–F133.
6. G.Argentin, R.Cicchetti 2004 Genotoxic and antiapoptotic effect of nicotine on human gingival fibroblasts. Toxicol Sci. 79:75–81.
7. J.Banerjee, H.A.Al-Wadei, M.H.Al-Wadei, K.Dagnon, H.M.Schuller 2014. Differential modulation of nicotine-induced gemcitabine resistance by GABA receptor agonists in pancreatic cancer cell xenografts and in vitro. BMC Cancer. 14:725.
8. J.Banerjee, H.A.N.Al-Wadei, H.M.Schuller 2013. Chronic nicotine inhibits the therapeutic effects of gemcitabine on pancreatic cancer in vitro and in mouse xenografts. Eur J Cancer. 49:1152–1158.
9. J.H.Bavarva, H.Tae, L.McIver, H.R.Garner 2014. Nicotine and oxidative stress induced exomic variations are concordant and overrepresented in cancer-associated genes. Oncotarget. 5:4788–4798.
10. N.L.Benowitz 2011. Smokeless tobacco as a nicotine delivery device:harm or harm reduction? Clin Pharmacol Ther. 90:491–493.
11. N.L.Benowitz 2014. Emerging nicotine delivery products. Implications for public health. Ann Am Thorac Soc. 11:231–235.
12. N.L.Benowitz, J.Hukkanen, P.JacobIII. 2009. Nicotine chemistry, metabolism, kinetics and biomarkers. Handb Exp Pharmacol. 192:29–60.
13. M.R.Berger, W.J.Zeller 1988. Interaction of nicotine with anticancer treatment. Klin Wochenschr. 66:127–133.
14. V.P.Bersch, A.B.Osvaldt, M.I.Edelweiss, R.C.Schumacher, L.R.Wendt, L.P.Abreu, C.B.Blom, G.P.Abreu, L.Costa, P.Piccinini,. 2009. Effect of nicotine and cigarette smoke on an experimental model of intraepithelial lesions and pancreatic adenocarcinoma induced by 7,12-dimethylbenzanthracene in mice. Pancreas. 38:65–70.
15. B.Bhagat, M.W.Rana 1971. Antitumor activity of antiserum nerve growth factor (anti-NGF). Proc Soc Exp Biol Med. 138:983–984.
16. F.G.Bock 1980. Cocarcinogenic properties of nicotine. In:G.B.Gori, F.G.Bock, editors. A safe cigarette? Cold Spring Harbor (NY):Cold Spring Harbor Laboratory. p. 129–136.
17. F.G.Bock, T.C.Tso 1976. Chemical and biological identification of tumorigenic components of tobacco. In:E.L.Wynder, D.Hoffmann, G.B.Gori, editors. Proceedings of the third world conference on smoking and health. Washington (DC):Government Printing Office. p. 161–174.
18. E.Boyland 1968. The possible carcinogenic action of alkaloids of tobacco and betel nut. Planta Med. 1968:13–23.
19. K.C.Brown, H.E.Perry, J.K.Lau, D.V.Jones, J.F.Pulliam, B.A.Thornhill, C.M.Crabtree, H.Luo, Y.C.Chen, P.Dasgupta 2013. Nicotine induces the up-regulation of the α7-nicotinic receptor (α7-nAChR) in human squamous cell lung cancer cells via the Sp1/GATA protein pathway. J Biol Chem. 288:33049–33059.
20. A.Cardinale, C.Nastrucci, A.Cesario, P.Russo 2012. Nicotine:specific role in angiogenesis, proliferation and apoptosis. Crit Rev Toxicol. 42:68–89.
21. Y.P.Chen, G.K.Johnson, C.A.Squier 1994. Effects of nicotine and tobacco-specific nitrosamines on hamster cheek pouch and gastric mucosa. J Oral Pathol Med. 23:251–255.
22. Y.P.Chen, C.A.Squier 1990. Effect of nicotine on 7,12-dimethylbenz[a]anthracene carcinogenesis in hamster cheek pouch. J Natl Cancer Inst. 82:861–864.
23. S.Y.Cheng, D.Glazkova, E.L.Serova Sabban 2005. Effect of prolonged nicotine infusion on response of rat catecholamine biosynthetic enzymes to restraint and cold stress. Pharmacol Biochem Behav. 82:559–568.
24. K.M.Chu, C.H.Cho, V.Y.Shin 2013. Nicotine and gastrointestinal disorders:its role in ulceration and cancer development. Curr Pharm Des. 19:5–10.
25. D.B.Clayson 1974. Editorial:bladder carcinogenesis in rats and mice:possibility of artifacts. J Natl Cancer Inst. 52:1685–1689.
26. S.M.Cohen, L.B.Ellwein 1991. Genetic errors, cell proliferation, and carcinogenesis. Cancer Res. 51:6493–6505.
27. R.Davis, W.Rizwani, S.Banerjee, M.Kovacs, E.Haura, D.Coppola, S.Chellappan 2009. Nicotine promotes tumor growth and metastasis in mouse models of lung cancer. PLoS One. 4:e7524.
28. O.Demirhan, C.Demir, E.Tunc, N.nandiklioglu, E.Sutcu, N.Sadikoglu, B.Ozcan 2011. The genotoxic effect of nicotine on chromosomes of human fetal cells:the first report described as an important study. Inhal Toxicol. 23:829–834.
29. G.E.Dinse, S.D.Peddada, S.F.Harris, S.A.Elmore 2010. Comparison of NTP historical control tumor incidence rates in female Harlan Sprague Dawley and Fischer 344/N Rats. Toxicol Pathol. 38:765–775.
30. D.J.Doolittle, R.Winegar, C.K.Lee, W.S.Caldwell, A.W.Hayes, J.D.de Bethizy 1995. The genotoxic potential of nicotine and its major metabolites. Mutat Res. 344:95–102.
31. O.Eränkö, V.Hopsu, L.Räisäinen 1959a. Changes induced by prolonged administration of nicotine in the distributions of cholinesterases and acid phosphatase in the adrenal medulla of the rat. J Neurochem. 4:332–337.
32. O.Eränkö, V.Hopsu, L.Räisäinen 1959b. Effect of prolonged administration nicotine on the medullary volume and the distribution of noradrenaline in the adrenals of the rat, the mouse and the guinea pig. Endocrinology. 65:293–297.
33. S.Feng, S.Kapur, M.Sarkar, R.Muhammad, P.Mendes, K.Newland, H.J.Roethig 2007. Respiratory retention of nicotine and urinary excretion of nicotine and its five major metabolites in adult male smokers. Toxicol Lett. 173:101–106.
34. J.W.Flora, N.Meruva, C.B.Huang, C.T.Wilkinson, R.Ballentine, D.C.Smith, M.S.Werley, W.J.McKinney 2016. Characterization of potential impurities and degradation products in electronic cigarette formulations and aerosols. Regul Toxicol Pharmacol. 74:1–11.
35. B.L.Freedlander, F.A.French 1956. Absence of co-carcinogenic action of oxidation products of nicotine in initiation of pulmonary adenomas in mice with urethane. Proc Am Assoc Cancer Res. 2:109.
36. B.L.Freedlander, F.A.French, A.Furst 1956. The nonadditive effect of nicotine and nicotine N-oxide on the carcinogenicity of ultraviolet light. Proc Am Assoc Cancer Res. 2:109.
37. L.M.Fucito, M.P.Bars, A.Forray, A.M.Rojewski, S.Shiffman, P.Selby, R.West, J.Foulds, B.A.Toll Writing Committee for the SRNT Policy and Treatment Networks. 2014. Addressing the evidence for FDA nicotine replacement therapy label changes:a policy statement of the Association for the Treatment of Tobacco Use and Dependence and the Society for Research on Nicotine and Tobacco. Nicotine Tob Res. 16:909–914.
38. V.Galitovskiy, A.I.Chernyavsky, R.A.Edwards, S.A.Grando 2012. Muscle sarcomas and alopecia in A/J mice chronically treated with nicotine. Life Sci. 91:1109–1112.
39. C.L.Gaworski, R.Lemus-Olalde, E.L.Carmines 2008. Toxicological evaluation of potassium sorbate added to cigarette tobacco. Food Chem Toxicol. 46:339–351.
40. C.Ginzkey, G.Steussloff, C.Koehler, M.Burghartz, A.Scherzed, S.Hackenberg, R.Hagen, N.H.Kleinsasser 2014a. Nicotine derived genotoxic effects in human primary parotid gland cells as assessed in vitro by comet assay, cytokinesis-block micronucleus test and chromosome aberrations test. Toxicol in Vitro. 28:838–846.
41. C.Ginzkey, G.Steussloff, C.Koehler, S.Hackenberg, E.Richter, R.Hagen, N.H.Kleinsasser 2014b. Nicotine causes genotoxic damage but is not metabolized during long-term exposure of human nasal miniorgan cultures. Toxicol Lett. 229:303–310.
42. C.Ginzkey, T.Stueber, G.Friehs, C.Koehler, S.Hackenberg, E.Richter, R.Hagen, N.H.Kleinsasser 2012. Analysis of nicotine-induced DNA damage in cells of the human respiratory tract. Toxicol Lett. 208:23–29.
43. C.Ginzkey, G.Friehs, C.Koehler, S.Hackenberg, R.Hagen, N.H.Kleinsasser 2013. Assessment of nicotine-induced DNA damage in a genotoxicological test battery. Mutat Res Genet Toxicol Environ Mutagen. 751:34–39.
44. J.E.Goodman, R.L.Prueitt, S.N.Sax, L.A.Bailey, L.R.Rhomberg 2013. Evaluation of the causal framework used for setting national ambient air quality standards. Crit Rev Toxicol. 43:829–849.
45. J.E.Goodman, R.L.Prueitt, S.N.Sax, H.N.Lynch, K.Zu, J.C.Lemay, J.M.King, F.J.Venditti 2014. Weight-of-evidence evaluation of short-term ozone exposure and cardiovascular effects. Crit Rev Toxicol. 44:725–790.
46. S.D.Grabus, B.R.Martin, A.M.Batman, R.F.Tyndale, E.Sellers, M.I.Damaj 2005. Nicotine physical dependence and tolerance in the mouse following chronic oral administration. Psychopharmacology (Berlin). 178:183–192.
47. S.A.Grando 2014. Connections of nicotine to cancer. Nat Rev Cancer. 14:419–429.
48. H.Greim, A.Hartwig, U.Reuter, H.B.Richter-Reichhelm, H.W.Thielmann 2009. Chemically induced pheochromocytomas in rats:mechanisms and relevance for human risk assessment. Crit Rev Toxicol. 39:695–718.
49. J.L.Guerriero, D.Ditsworth, J.M.Catanzaro, G.Sabino, M.B.Furie, R.R.Kew, H.C.Crawford, W.Zong 2011. DNA alkylating therapy induces tumor regression through an HMGB1-mediated activation of innate immunity. J Immunol. 186:3517–3526.
50. V.K.Gurkalo, N.I.Volfson 1982. Nicotine influence upon the development of experimental stomach tumors. Arch Geschwulstforsch. 52:259–265.
51. M.Habs, D.Schmähl 1976. Influence of five different postnatal lifelong treatments on the transplacental carcinogenicity of ethylnitrosourea in Sprague–Dawley rats. Cancer Lett. 2:93–100.
52. M.Habs, D.Schmähl 1984. Influence of nicotine on N-nitrosomethylurea-induced mammary tumors in rats. Klin Wochenschr. 62:105–108.
53. Y.Han, M.T.Ling, H.Mao, J.Zheng, M.Liu, K.T.Lam, Y.Liu, W.Tu, Y.L.Lau 2014. Influenza virus-induced lung inflammation was modulated by cigarette smoke exposure in mice. PLoS One. 9:e86166.
54. J.Hao, F.D.Shi, M.Abdelwahab, S.X.Shi, A.Simard, P.Whiteaker, R.Lukas, Q.Zhou 2013. Nicotinic receptorβ2 determines NK cell-dependent metastasis in a murine model of metastatic lung cancer. PLoS One. 8:e57495.
55. H.-J.Haussmann, B.Gerstenberg, W.Göcke, P.Kuhl, G.Schepers, R.Stabbert, W.Stinn, A.Teredesai, F.J.Tewes 1998. 12-Month inhalation study on room-aged cigarette sidestream smoke in rats. Inhal Toxicol. 10:663–697.
56. S.Hayashi, T.Hamada, S.F.Zaidi, M.Oshiro, J.Lee, T.Yamamoto, Y.Ishii, M.Sasahara, M.Kadowaki 2014. Nicotine suppresses acute colitis and colonic tumorigenesis associated with chronic colitis in mice. Am J Physiol Gastrointest Liver Physiol. 307:G968–G978.
57. S.S.Hecht 2012a. Research opportunities related to establishing standards for tobacco products under the Family Smoking Prevention and Tobacco Control Act. Nicotine Tob Res. 14:18–28.
58. S.S.Hecht 2012b. Lung carcinogenesis by tobacco smoke. Int J Cancer. 131:2724–2732.
59. S.S.Hecht, A.Rivenson, J.Braley, J.Di Bello, J.D.Adams, D.Hoffmann 1986. Induction of oral cavity tumors in F344 rats by tobacco-specific nitrosamines and snuff. Cancer Res. 46:4162–4166.
60. C.Heeschen, J.J.Jang, M.Weis, A.Pathak, S.Kaji, R.S.Hu, P.S.Tsao, F.L.Johnson, J.P.Cooke 2001. Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis. Nat Med. 7:833–839.
61. P.C.Hermann, P.Sancho, M.Cañamero, P.Martinelli, F.Madriles, P.Michl, T.Gress, R.de Pascual, L.Gandia, C.Guerra,. 2014. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice. Gastroenterology. 147:1119–1133.
62. A.B.Hill 1965. The environment and disease:association or causation? Proc R Soc Med. 58:295–300.
63. D.Hoffmann, J.D.Adams, D.Lisk, I.Fisenne, K.D.Brunnemann 1987. Toxic and carcinogenic agents in dry and moist snuff. J Natl Cancer Inst. 79:1281–1286.
64. W.C.Hueper 1943. Experimental studies in cardiovascular pathology. VII. Chronic nicotine poisoning in rats and dogs. Arch Pathol. 35:846–856.
65. J.Hukkanen, I.I.I.P.Jacob, N.L.Benowitz 2005.Metabolism and disposition kinetics of nicotine. Pharmacol Rev. 57:79–115.
66. M.R.Improgo, L.G.Soll, A.R.Tapper, P.D.Gardner 2013. Nicotinic acetylcholine receptors mediate lung cancer growth. Front Physiol. 4:1–6. doi:10.3389/fphys.2013.00251.
67. M.Improgo, A.R.Tapper, P.D.Gardner 2011. Nicotinic acetylcholine receptor-mediated mechanisms in lung cancer. Biochem Pharmacol. 82:1015–1021.
68. International Agency for Research on Cancer. 2007. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, vol. 89, Smokeless Tobacco and Some Tobacco-specific N-Nitrosamines. Lyon, France:World Health Organization.
69. International Agency for Research on Cancer. 2012. A Review of Human Carcinogens, Part E:Personal Habits and Indoor Combustions. [cited 2015 Mar 26]. Available from:http://monographs.iarc.fr/ENG/Monographs/vol100E/mono100E.pdf/.
70. A.R.Iskandar, C.Liu, D.E.Smith, K.Q.Hu, S.W.Choi, L.M.Ausman, X.D.Wang 2013. β-Cryptoxanthin restores nicotine-reduced lung SIRT1 to normal levels and inhibits nicotine-promoted lung tumorigenesis and emphysema in A/J mice. Cancer Prev Res(Phila). 6:309–320.
71. N.Ito, S.Fukushima, T.Shirai, A.Hagiwara, K.Imaida 1984. Drugs, food additives and natural products as promoters in rat urinary bladder carcinogenesis. IARC Sci Publ. 56:399–407.
72. M.Jarvis, H.Tunstall-Pedoe, C.Feyerabend, C.Vesey, Y.Salloojee 1984. Biochemical markers of smoke absorption and self reported exposure to passive smoking. J Epidemiol Community Health. 38:335–339.
73. M.J.Jarzynka, P.Guo, I.Bar-Joseph, B.Hu, S.Y.Cheng 2006. Estradiol and nicotine exposure enhances A549 bronchioloalveolar carcinoma xenograft growth in mice through the stimulation of angiogenesis. Int J Oncol. 28:337–344.
74. K.Jensen, S.Afroze, M.K.Munshi, M.Guerrier, S.S.Glaser 2012. Mechanisms for nicotine in the development and progression of gastrointestinal cancers. Transl Gastrointest Cancer. 1:81–87.
75. R.Kalra, S.P.Singh, J.C.Pena-Philippides, R.J.Langley, S.Razani-Boroujerdi, M.L.Sopori 2004. Immunosuppressive and anti-inflammatory effects of nicotine administered by patch in an animal model. Clin Diagn Lab Immunol. 11:563–568.
76. A.A.Khalil, M.J.Jameson, W.C.Broaddus, P.S.Lin, T.D.Chung 2013. Nicotine enhances proliferation, migration, and radioresistance of human malignant glioma cells through EGFR activation. Brain Tumor Pathol. 30:73–83.
77. J.E.Klaunig 2013. Chapter 8:chemical carcinogenesis. In:C.D.Klaassen, editor. Casarett and Doull's toxicology:the basic science of poison. New York:McGraw-Hill.
78. N.H.Kleinsasser, A.W.Sassen, M.P.Semmler, U.A.Harreus, A.K.Licht, E.Richter 2005. The tobacco alkaloid nicotine demonstrates genotoxicity in human tonsillar tissue and lymphocytes. Toxicol Sci. 86:309–317.
79. U.Klier, C.Maletzki, N.Gottmann, B.Kreikemeyer, M.Linnebacher 2011. Avitalized bacteria mediate tumor growth control via activation of innate immunity. Cell Immunol. 269:120–127.
80. H.J.Klimisch, M.Andreae, U.Tillmann 1997. A systematic approach for evaluating the quality of experimental toxicological and ecotoxicological data. Regul Toxicol Pharmacol. 25:1–5.
81. A.S.Kosdoba 1930. Zur Frage der experimentellen Pathologie der Nebennieren bei intravenöser Nicotineinverleibung [On the question of experimental pathology of the adrenals upon intravenous nicotine application]. Arch Klin Chir. 156:550–566.
82. G.A.Kyerematen, L.H.Taylor, J.D.de Bethizy, E.S.Vesell 1988. Pharmacokinetics of nicotine and 12 metabolites in the rat. Application of a new radiometric high performance liquid chromatography assay. Drug Metab Dispos. 16:125–129.
83. D.C.Lam, S.Y.Luo, K.H.Fu, M.M.Lui, K.H.Chan, I.I.Wistuba, B.Gao, S.W.Tsao, M.S.Ip, J.D.Minna 2016. Nicotinic acetylcholine receptor expression in human airway correlates with lung function. Am J Physiol Lung Cell Mol Physiol. 310:L232–L239.
84. J.M.Landau, Z.Y.Wang, G.Y.Yang, W.Ding, C.S.Yang 1998. Inhibition of spontaneous formation of lung tumors and rhabdomyosarcomas in A/J mice by black and green tea. Carcinogenesis. 19:501–507.
85. P.S.Larson, H.B.Haag, H.Silvette 1961. Tobacco – experimental and clinical studies, a comprehensive account of the world literature. Baltimore (MD):The Williams & Wilkins Company.
86. E.J.La Voie, A.Shigematsu, A.Rivenson, B.Mu, D.Hoffmann 1985. Evaluation of the effects of cotinine and nicotine-N'-oxides on the development of tumors in rats initiated with N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide. J Natl Cancer Inst. 75:1075–1081.
87. C.H.Lee, C.S.Huang, C.S.Chen, S.H.Tu, Y.J.Wang, Y.J.Chang, K.W.Tam, P.L.Wei, T.C.Cheng, J.S.Chu,. 2010. Overexpression and activation of the alpha9-nicotinic receptor during tumorigenesis in human breast epithelial cells. J Natl Cancer Inst. 102:1322–1335.
88. C.H.Lee, C.H.Wu, Y.S.Ho 2011. From smoking to cancers:novel targets to neuronal nicotinic acetylcholine receptors. J Oncol. 2011:693424.
89. J.Lee, J.P.Cooke 2012. Nicotine and pathological angiogenesis. Life Sci. 91:1058–1064.
90. L.S.Levy, P.A.Martin 1989. Toxicology of nicotine – its role in the aetiology of cancer due to cigarette smoking and cardiovascular disease. In:N.Wald, P.Froggatt, editors. Nicotine, smoking, and the low tar programme. Oxford:Oxford University Press. p. 11–23.
91. H.Li, S.Wang, K.Takayama, T.Harada, I.Okamoto, E.Iwama, A.Fujii, K.Ota, N.Hidaka, Y.Kawano,. 2015. Nicotine induces resistance to erlotinib via cross-talk between α 1 nAChR and EGFR in the non-small cell lung cancer xenograft model. Lung Cancer. 88:1–8.
92. D.Liu, F.Pan, B.Li, X.Han, W.Li, Y.Shi, Z.Pang, Q.Zhang 2011. Intervention of nicotine on MNU-induced bladder cancer in rats. J Huazhong Univ Sci Technol Med Sci. 31:103–106.
93. W.Liu, D.D.Yi, J.L.Guo, Z.X.Xiang, L.F.Deng, L.He 2015. Nuciferine, extracted from Nelumbo nucifera Gaertn, inhibits tumor-promoting effect of nicotine involving Wnt/β-catenin signaling in non-small cell lung cancer. J Ethnopharmacol. 165:83–93.
94. C.R.Maier, M.C.Hollander, E.A.Hobbs, I.Dogan, R.I.Linnoila, P.A.Dennis 2011. Nicotine does not enhance tumorigenesis in mutant K-ras-driven mouse models of lung cancer. Cancer Prev Res(Phila). 4:1743–1751.
95. G.Manenti, T.A.Dragani 2005. Pas1 haplotype-dependent genetic predisposition to lung tumorigenesis in rodents:a meta-analysis. Carcinogenesis. 26:875–882.
96. M.J.Marks, J.A.Stitzel, A.C.Collins 1985. Time course study of the effects of chronic nicotine infusion on drug response and brain receptors. J Pharmacol Exp Ther. 235:619–628.
97. S.G.Matta, D.J.Balfour, N.L.Benowitz, R.T.Boyd, J.J.Buccafusco, A.R.Caggiula, C.R.Craig, A.C.Collins, M.I.Damaj, E.C.Donny,. 2007. Guidelines on nicotine dose selection for in vivo research. Psychopharmacology (Berlin). 190:269–319.
98. J.L.Mauderly, W.E.Bechtold, J.A.Bond, A.L.Brooks, B.T.Chen, R.G.Cuddihy, J.R.Harkema, R.F.Henderson, N.F.Johnson, K.Rithidech 1989. Comparison of 3 methods of exposing rats to cigarette smoke. Exp Pathol. 37:194–197.
99. A.Molfino, F.Logorelli, G.Citro, G.Bertini, C.Ramaccini, M.R.Bollea, F.F.Rossi, A.Laviano 2011. Stimulation of the nicotine antiinflammatory pathway improves food intake and body composition in tumor-bearing rats. Nutr Cancer. 63:295–299.
100. S.H.Moolgavkar, A.G.J.Knudson 1981. Mutation and cancer:a model for human carcinogenesis. J Natl Cancer Inst. 66:1037–1052.
101. S.E.Murphy, L.B.von Weymarn, M.M.Schutten, F.Kassie, J.F.Modiano 2011. Chronic nicotine consumption does not influence 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis. Cancer Prev Res (Phila). 4:1752–1760.
102. R.P.Murray, J.E.Connett, L.M.Zapawa 2009. Does nicotine replacement therapy cause cancer? Evidence from the Lung Health Study. Nicotine Tob Res. 11:1076–1082.
103. T.Nakada, K.Kiyotani, S.Iwano, T.Uno, M.Yokohira, K.Yamakawa, M.Fujieda, T.Saito, H.Yamazaki, K.Imaida,. 2012. Lung tumorigenesis promoted by anti-apoptotic effects of cotinine, a nicotine metabolite through activation of PI3K/Akt pathway. J Toxicol Sci. 37:555–563.
104. T.Natori, M.Sata, M.Washida, Y.Hirata, R.Nagai, M.Makuuchi 2003. Nicotine enhances neovascularization and promotes tumor growth. Mol Cells. 16:143–146.
105. A.Nishikawa, F.Furukawa, T.Imazawa, H.Yoshimura, K.Mitsumori, M.Takahashi 1992. Effects of caffeine, nicotine, ethanol and sodium selenite on pancreatic carcinogenesis in hamsters after initiation with N-nitrosobis(2-oxopropyl)amine. Carcinogenesis. 13:1379–1382.
106. X.M.Niu, S.Lu 2014. Acetylcholine receptor pathway in lung cancer:new twists to an old story. World J Clin Oncol. 5:667–676.
107. Organisation for Economic Co-operation and Development. 2009. OECD guideline for the testing of chemicals. 451 Carcinogenicity studies. Paris:OECD Publishing.
108. L.Paleari, A.Catassi, M.Ciarlo, Z.Cavalieri, C.Bruzzo, D.Servent, A.Cesario, L.Chessa, M.Cilli, F.Piccardi,. 2008. Role of alpha7-nicotinic acetylcholine receptor in human non-small cell lung cancer proliferation. Cell Prolif. 41:936–959.
109. D.R.Petersen, K.J.Norris, J.A.Thompson 1984. A comparative study of the disposition of nicotine and its metabolites in three inbred strains of mice. Drug Metab Dispos. 12:725–731.
110. K.Pietilä, I.Laakso, L.Ahtee 1995. Chronic oral nicotine administration affects the circadian rhythm of dopamine and 5-hydroxytryptamine metabolism in the striata of mice. Naunyn Schmiedebergs Arch Pharmacol. 353:110–115.
111. S.Pillai, J.Trevino, B.Rawal, S.Singh, M.Kovacs, X.Li, M.Schell, E.Haura, G.Bepler, S.Chellappan 2015. β-Arrestin-1 mediates nicotine-induced metastasis through E2F1 target genes that modulate epithelial–mesenchymal transition. Cancer Res. 75:1009–1020.
112. G.Pratesi, S.Cervi, A.Balsari, G.Bondiolotti, L.M.Vicentini 1996. Effect of serotonin and nicotine on the growth of a human small cell lung cancer xenograft. Anticancer Res. 16:3615–3619.
113. G.Prokopczyk, J.D.Adams, E.J.La Voie, D.Hoffmann 1987. Effect of snuff and nicotine on DNA methylation by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Carcinogenesis. 8:1395–1397.
114. R.L.Prueitt, H.N.Lynch, K.Zu, S.N.Sax, F.J.Venditti, J.E.Goodman 2014. Weight-of-evidence evaluation of long-term ozone exposure and cardiovascular effects. Crit Rev Toxicol. 44:791–822.
115. M.W.Rana, B.Bhagat 1970. Chemical carcinogenesis in immunosympathectomized mice. Anat Rec. 166:365.
116. A.Renda, R.Nashmi 2014. Chronic nicotine pretreatment is sufficient to upregulate α4 nicotinic receptors and increase oral nicotine self-administration in mice. BMC Neurosci. 15:89.
117. L.R.Rhomberg, L.A.Bailey, J.E.Goodman, A.K.Hamade, D.Mayfield 2011. Is exposure to formaldehyde in air causally associated with leukemia? – a hypothesis-based weight-of-evidence analysis. Crit Rev Toxicol. 41:555–621.
118. L.R.Rhomberg, J.E.Goodman, L.A.Bailey, R.L.Prueitt, N.B.Beck, C.Bevan, M.Honeycutt, N.E.Kaminski, G.Paoli, L.H.Pottenger,. 2013. A survey of frameworks for best practices in weight-of-evidence analyses. Crit Rev Toxicol. 43:753–784.
119. H.Rubin 2001. Synergistic mechanisms in carcinogenesis by polycyclic aromatic hydrocarbons and by tobacco smoke:a bio-historical perspective with updates. Carcinogenesis. 22:1903–1930.
120. H.Rubin 2002. Selective clonal expansion and microenvironmental permissiveness in tobacco carcinogenesis. Oncogene. 21:7392–7411.
121. P.Russo, A.Cardinale, S.Margaritora, A.Cesario 2012. Nicotinic receptor and tobacco-related cancer. Life Sci. 91:1087–1092.
122. T.Sanner, T.K.Grimsrud 2015. Nicotine:carcinogenicity and effects on response to cancer treatment-a review. Front Oncol. 5:196.
123. C.Schaal, S.P.Chellappan 2014. Nicotine-mediated cell proliferation and tumor progression in smoking-related cancers. Mol Cancer Res. 12:14–23.
124. G.Schepers, K.Rustemeier, R.A.Walk, U.Hackenberg 1993. Metabolism of S-nicotine in noninduced and aroclor-induced rats. Eur J Drug Metab Pharmacokinet. 18:187–197.
125. H.Schievelbein 1962. Nikotin, Rauchen und Organismus [Nicotine, smoking and organism]. Beitr Tabakforsch Int. 1:199–274.
126. D.Schmähl, M.Habs 1976. Life-span investigations for carcinogenicity of some immune-stimulating, immunodepressive and neurotropic substances in Sprague–Dawley rats. Z Krebsforsch Klin Onkol Cancer Res Clin Oncol. 86:77–84.
127. D.Schmähl, H.Osswald 1968. Fehlen einer carcinogenen Wirkung von Cotinin bei Ratten [Lack of a carcinogenic effect of cotinine in rats]. Zeitschrift Für Krebsforschung. 71:198.
128. N.G.Schneider, R.E.Olmstead, M.A.Franzon, E.Lunell 2001. The nicotine inhaler:clinical pharmacokinetics and comparison with other nicotine treatments. Clin Pharmacokinet. 40:661–684.
129. R.Schoental, M.A.Head 1953. Tobacco alkaloids. In:31st Annual Report. British Empire Cancer Campaign; p. 269.
130. H.M.Schuller 2012. Regulatory role of the α7nAChR in cancer. Curr Drug Targets. 13:680–687.
131. H.M.Schuller 2014. Impact of neuro-psychological factors on smoking-associated lung cancer. Cancers (Basel). 6:580–594.
132. H.M.Schuller, M.D.McGavin, M.Orloff, A.Riechert, B.Porter 1995. Simultaneous exposure to nicotine and hyperoxia causes tumors in hamsters. Lab Invest. 73:448–456.
133. L.Shahab, L.S.Brose, R.West 2013. Novel delivery systems for nicotine replacement therapy as an aid to smoking cessation and for harm reduction:rationale, and evidence for advantages over existing systems. CNS Drugs. 27:1007–1019.
134. P.G.Shields 2011. Long-term nicotine replacement therapy:cancer risk in context. Cancer Prev Res(Phila). 4:1719–1723.
135. V.Y.Shin, W.K.Wu, Y.N.Ye, W.H.So, M.W.Koo, E.S.Liu, J.C.Luo, C.H.Cho 2004. Nicotine promotes gastric tumor growth and neovascularization by activating extracellular signal-regulated kinase and cyclooxygenase-2. Carcinogenesis. 25:2487–2495.
136. L.D.Shultz, N.Goodwin, F.Ishikawa, V.Hosur, B.L.Lyons, D.L.Greiner 2014. Human cancer growth and therapy in immunodeficient mouse models. Cold Spring Harbor Protocol. 2014:694–708.
137. S.Singh, S.Pillai, S.Chellappan 2011. Nicotinic acetylcholine receptor signaling in tumor growth and metastasis. J Oncol. 2011:456743.
138. E.C.K.Siu, R.F.Tyndale 2007. Characterization and comparison of nicotine and cotinine metabolism in vitro and in vivo in DBA/2 and C57BL/6 mice. Mol Pharmacol. 71:826–834.
139. J.A.Sparks, J.R.Pauly 1999. Effects of continuous oral nicotine administration on brain nicotinic receptors and responsiveness to nicotine in C57Bl/6 mice. Psychopharmacology (Berl). 141:145–153.
140. M.Staemmler 1935. Die chronische Vergiftung mit Nicotin. Ergebnisse experimenteller Untersuchungen an Ratten [Chronic poisoning with nicotine. Results of experimental studies in rats]. Vichows Archiv. 295:366–393.
141. M.Staemmler 1936. Über geschwulstartige Bildungen im Nebennierenmark als Folge experimenteller Nicotinvergiftungen [Tumor-like developments in the adrenal medulla as a consequence of experimental nicotine poisoning]. Klin Wochenschr. 15:404–407.
142. W.Stinn, A.Berges, K.Meurrens, A.Buettner, S.Gebel, R.B.Lichtner, K.Janssens, E.Veljkovic, Y.Xiang, E.Roemer,. 2013. Towards the validation of a lung tumorigenesis model with mainstream cigarette smoke inhalation using the A/J mouse. Toxicology. 305:49–64.
143. G.D.Stoner, M.B.Shimkin 1982. Strain A mouse lung tumor assay. J Am Coll Toxicol. 1:145–169.
144. E.H.Theophilus, J.R.Hayes, R.J.Potts, P.H.Ayres, C.D.Williams, C.D.Garner 2012. Toxicological evaluation of smokeless tobacco:90-day rodent feeding studies. Exp Toxicol Pathol. 64:15–24.
145. C.H.Thienes 1960. Chronic nicotine poisoning. Ann N Y Acad Sci. 90:239–248.
146. J.G.Thompson, F.D.Irwin, S.Kanematsu, K.Seraydarian, M.Suh 1973. Effects of chronic nicotine administration and age in male Fischer-344 rats. Toxicol Appl Pharmacol. 26:606–620.
147. B.Toth 1982. Effects of long term administration of nicotine hydrochloride and nicotinic acid in mice. Anticancer Res. 2:71–73.
148. J.G.Treviño, S.Pillai, S.Kunigal, S.Singh, W.J.Fulp, B.A.Centeno, S.P.Chellappan 2012. Nicotine induces inhibitor of differentiation-1 in a Src-dependent pathway promoting metastasis and chemoresistance in pancreatic adenocarcinoma. Neoplasia. 14:1102–1114.
149. R.Truhaut, M.De Clercq 1961. Sur le rôle éventuel de la nicotine et de ses dérivés de pyrogénation dans les phénomènes de cancérisation [On the eventual role of nicotine and its derivatives of pyrogenation in the phenomena of canceration]. C R Hebd Seances Acad Sci. 253:1506–1508.
150. R.Truhaut, M.De Clercq, F.Loisillier 1964. Sur les toxicitès aiguë et chronique de la cotinine, et sur son effet cancérigène chez le rat [On the acute and chronic toxicity of cotinine, and on its cancerogenic effect in the rat]. Pathol Biol (Paris). 12:39–42.
151. UK Royal College of Physicians. 2007. Harm reduction in nicotine addiction. Helping people who can't quit. [cited 2015 Jun 16]. Available from:http://www.tobaccoprogram.org/pdf/4fc74817-64c5-4105-951e-38239b09c5db.pdf/.
152. US Department of Health and Human Services. 2014. The health consequences of smoking – 50 years of progress. A report of the Surgeon General. [cited 2015 Jun 16]. Available from:http://www.surgeongeneral.gov/library/reports/50-years-of-progress/full-report.pdf/.
153. US Food and Drug Administration. 2013. Modifications to labeling of nicotine replacement therapy products for over-the-counter human use. Fed Regist. 78:19718–19721.
154. US Food and Drug Administration. 2015. Drugs@FDA, Nicorette. [cited 2016 Mar 7]. Available from:http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm/.
155. C.von Otto 1911. Über anatomische Veränderungen des Herzens infolge von Nikotin (Experimentalstudie) [About anatomical changes of the heart due to nicotine (experimental study)]. Arch Path Anat. 205:384–397.
156. H.L.Waldum, O.G.Nilsen, T.Nilsen, H.Rørvik, U.Syversen, A.K.Sandvik, O.A.Haugen, S.H.Torp, E.Brenna 1996. Long-term effects of inhaled nicotine. Life Sci. 58:1339–1346.
157. G.W.Warren, A.K.Singh 2013. Nicotine and lung cancer. J Carcinog. 12:1.
158. G.W.Warren, M.A.Romano, M.R.Kudrimoti, M.E.Randall, R.C.McGarry, A.K.Singh, V.M.Rangnekar 2012. Nicotinic modulation of therapeutic response in vitro and in vivo. Int J Cancer. 131:2519–2527.
159. M.S.Werley, A.M.Jerome, M.J.Oldham 2014. Toxicological evaluation of aerosols of a tobacco extract formulation and nicotine formulation in acute and short-term inhalation studies. Inhal Toxicol. 26:207–221.
160. C.C.Willhite, N.A.Karyakina, R.A.Yokel, N.Yenugadhati, T.M.Wisniewski, I.M.Arnold, F.Momoli, D.Krewski 2014. Systematic review of potential health risks posed by pharmaceutical, occupational and consumer exposures to metallic and nanoscale aluminum, aluminum oxides, aluminum hydroxide and its soluble salts. Crit Rev Toxicol. 44:1–80.
161. R.H.Wilson, F.De Eds 1936. Chronic nicotine toxicity:I. Feeding of nicotine sulfate, tannate, and bentonite. J Ind Hyg Toxicol. 18:553–564.
162. R.H.Wilson, J.B.McNaught, F.De Eds 1938. Chronic nicotine toxicity:IV. Effect of nicotine-containing diets on histology and weights of organs of albino rats. J Ind Hyg Toxicol. 20:468–481.
163. H.P.S.Wong, L.Yu, E.K.Y.Lam, E.K.K.Tai, W.K.K.Wu, C.H.Cho 2007. Nicotine promotes colon tumor growth and angiogenesis through β-adrenergic activation. Toxicol Sci. 97:279–287.
164. Y.N.Ye, E.S.Liu, V.Y.Shin, W.K.Wu, J.C.Luo, C.H.Cho 2004. Nicotine promoted colon cancer growth via epidermal growth factor receptor, c-Src, and 5-lipoxygenase-mediated signal pathway. J Pharmacol Exp Ther. 308:66–72.
165. M.Yokohira, Y.Nakano, N.Hashimoto, K.Yamakawa, F.Ninomiya, S.Kishi, K.Saoo, K.Imaida 2012. Toxicity of nicotine by repeated intratracheal instillation to F344 rats. J Toxicol Pathol. 25:257–263.
166. C.C.Yu, Y.C.Chang 2013. Enhancement of cancer stem-like and epithelial-mesenchymal transdifferentiation property in oral epithelial cells with long-term nicotine exposure:reversal by targeting SNAIL. Toxicol Appl Pharmacol. 266:459–469.
167. M.A.Yu, A.Kiang, J.Wang-Rodriguez, E.Rahimy, M.Haas, V.Yu, L.G.Ellies, J.Chen, J.B.Fan, K.T.Brumund,. 2012. Nicotine promotes acquisition of stem cell and epithelial-to-mesenchymal properties in head and neck squamous cell carcinoma. PLoS One. 7:e51967.
168. K.Yuge, E.Kikuchi, M.Hagiwara, Y.Yasumizu, N.Tanaka, T.Kosaka, A.Miyajima, M.Oya 2015. Nicotine induces tumor growth and chemoresistance through activation of the PI3K/Akt/mTOR pathway in bladder cancer. Mol Cancer Ther. 14:2112–2120.
169. I.S.Yun, S.S.Kim 1938. Influence of continuous subcutaneous injection of nicotine on adrenal gland and anterior lobe of hypophysis. Trans Jap Pathol Soc. 28:426–428.
170. P.Zhou, B.Ma, W.He, D.Xu, X.Wang 2011. CpG oligodeoxynucleotide stimulates protective innate immunity against human renal cell carcinoma xenografted in nude mice. J Immunother. 34:535–541.